Phase IbII Study of TQB2825 Injection Combined With Immunochemotherapy for Adults Aged 18 to 80 With Diffuse Large B Cell Lymphoma

What this Trial Is About

Researchers are evaluating the safety and effectiveness of TQB2825 injection combined with immunochemotherapy in people with untreated or relapsedrefractory diffuse large B cell lymphoma DLBCL. This study includes both Phase 1b and Phase 2 stages and aims to measure outcomes such as the objective response rate, complete response rate, progression-free survival, duration of response, overall survival, and safety indicators like dose-limiting toxicity and maximum tolerated dose. Participants receive one of two treatment combinations TQB2825 injection plus the R-CHOP regimen which includes Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone or TQB2825 injection combined with Gemcitabine and Oxaliplatin GemOx. Each treatment cycle lasts 21 days. The study evaluates these treatments over these cycles to assess their effects on lymphoma. During the study, participants will undergo regular assessments including imaging scans, laboratory tests, and safety monitoring to track treatment response and side effects. Researchers will observe participants for up to two years to evaluate dose-limiting toxicity and maximum tolerated dose, and up to five years to assess overall survival. The study also tracks adverse events and serious adverse events throughout. Participation involves multiple visits for treatment and follow-up evaluations until study completion.

Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma